In today’s recent session, 9.79 million shares of the Aclaris Therapeutics Inc (NASDAQ:ACRS) have been traded, and its beta is 0.14. Most recently the company’s share price was $2.71, and it changed around $0.66 or 32.31% from the last close, which brings the market valuation of the company to $182.18M. ACRS at last check was trading at a discount to its 52-week high of $2.72, offering almost -0.37% off that amount. The share price’s 52-week low was $0.77, which indicates that the recent value has risen by an impressive 71.59% since then. We note from Aclaris Therapeutics Inc’s average daily trading volume that its 10-day average is 1.13 million shares, with the 3-month average coming to 560.23K.
Aclaris Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 13 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 7 recommended ACRS as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Aclaris Therapeutics Inc is expected to report earnings per share of -0.13 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aclaris Therapeutics Inc (NASDAQ:ACRS) trade information
Instantly ACRS has been showing a green trend so far today with a performance of 32.31% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.04 on recent trading dayincreased the stock’s daily price by 10.86%. The company’s shares are currently up 158.31% year-to-date, but still up 3.13% over the last five days. On the other hand, Aclaris Therapeutics Inc (NASDAQ:ACRS) is 127.92% up in the 30-day period. We can see from the shorts that 2.41 million shares have been sold at a short interest cover period of 3.56 day(s).
The consensus price target as assigned by Wall Street analysts is $14, which translates to bulls needing to increase their stock price by 80.64% from its current value. Analyst projections state that ACRS is forecast to be at a low of $3 and a high of $25.
Aclaris Therapeutics Inc (ACRS) estimates and forecasts
Aclaris Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 127.92 percent over the past six months and at a 58.06% annual growth rate that is well above the industry average of 15.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -570.00% in revenue this quarter, and will report an increase of 52.08% in the next quarter. The year-over-year growth rate is expected to be -50.89%, down from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 5.65M in revenue for the current quarter. 4 analysts expect Aclaris Therapeutics Inc to make 3.25M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 17.57M and 2.4M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -67.87%. Forecasts for the next quarter put sales growth at 35.69%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 20.67%.
ACRS Dividends
Aclaris Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-25.
Aclaris Therapeutics Inc (NASDAQ:ACRS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.66% of Aclaris Therapeutics Inc shares, and 73.55% of them are in the hands of institutional investors. The stock currently has a share float of 75.56%. Aclaris Therapeutics Inc stock is held by 107.0 institutions, with BML CAPITAL MANAGEMENT, LLC being the largest institutional investor. By 2024-06-30, it held 18.2739% of the shares, which is about 12.99 million shares worth $14.29 million.
VANGUARD GROUP INC, with 6.5952% or 4.69 million shares worth $5.16 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
